After a big setback on share price, I have thought on the last...

After a big setback on share price, I have thought on the last few announcements on the P3 trail, we have nailed with the science and drug. The only part of the failure is our own designed trial.

1. Rynocil- 9-1 vote with 90% mortality rate, YES I repeat again 90% mortality rate.

Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing.2 In patients with the most
severe form of acute GVHD (Grade C/D or III/IV) mortality is as high as 90% despite optimal institutional standard of care.3,4 There are currently no FDA-approved treatments in the United States for children under 12 with SR-aGVHD, a potentially life-threatening complication of an allogeneic bone marrow transplant for blood cancer.

2. CHF- 60% mortality rate, YES I repeat again 60% mortality rate.

Significant reduction in the incidence of non-fatal ischemic major adverse cardiac events (MACE) due to a heart attack (myocardial infarction, MI) or stroke (cerebrovascular accident, CVA) by 60% relative to controls in the total population of 537 patients (p=0.002); reduction in MACE was seen consistently across both New York Heart Association (NYHA) class II or III populations and irrespective of whether the underlying cause of heart failure was ischemic or non-ischemic.

3. COVID- Maybe less than 43% after receiving all kinds of drugs received sell on this planet. And still can save thousands of lives with this treatment. It's all about saving a life.

4. CLBP- Still to come.

If I have invested based on science and drug then yes I have won here but I can not control human error which is a type of trail design. Let's see time will tell, but still faith in science and drugs, human error can be solved with experience and additional efforts.